Log In
Print
BCIQ
Print
Print this Print this
 

Tykerb, Tyverb, lapatinib

Also known as: GW572016

  Manage Alerts
Collapse Summary General Information
Company Novartis AG
DescriptionHER1 and HER2 kinase inhibitor
Molecular Target Epidermal growth factor receptor 1 (EGFR1) (HER1) (ErbB1) ; Epidermal growth factor receptor 2 (HER2) (EGFR2) (ErbB2) (neu)
Mechanism of ActionEpidermal growth factor (EGF) receptor 2 (HER2) (ErbB2) (neu) inhibitor; Epidermal growth factor (EGF) receptor 1 (HER1) (ErbB1) inhibitor
Therapeutic ModalitySmall molecule

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$17,034.0M

$14,800.0M

$2,234.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today